-
Agilent Technologies recently reported strong fourth-quarter and full-year 2025 results, delivering robust organic revenue growth and providing positive earnings guidance for fiscal 2026 in the range of US$7.3 billion to US$7.4 billion.
-
A particularly material insight is Agilent’s continued momentum in core markets such as pharmaceuticals and biotech, with growth driven by new product innovation and operational efficiency improvements, even despite challenges in China and increased tax rates.
-
We’ll explore how Agilent’s raised 2026 revenue guidance reinforces the company’s investment narrative and projected margin expansion.
These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump’s tariffs. Discover why before your portfolio feels the trade war pinch.
To be a shareholder in Agilent Technologies, you need conviction in the company’s ability to deliver steady revenue growth from core end markets like pharma and biotech, even in the face of near-term volatility. The recently raised fiscal 2026 guidance underscores management’s confidence and supports the key short-term catalyst, ongoing product innovation and operational efficiency. At present, the biggest risk remains the continuing margin pressure from evolving global tariffs; while the new guidance is positive, the update does not materially alter this risk.
Among recent announcements, Agilent’s fourth-quarter and full-year 2025 earnings report stands out as particularly relevant. Not only did core revenue and earnings per share surpass last year’s numbers, but management’s guidance for 2026 core revenue growth of 4% to 6% directly addresses the company’s ability to sustain momentum. This remains closely tied to the impact of tariff-driven costs on margins and the effectiveness of its mitigation strategies.
By contrast, investors should also be aware that even as Agilent guides for margin expansion in 2026, supply chain and tariff-related margin pressures remain unresolved…
Read the full narrative on Agilent Technologies (it’s free!)
Agilent Technologies’ outlook anticipates $8.0 billion in revenue and $1.7 billion in earnings by 2028. This scenario is based on a 5.8% annual revenue growth rate and a $0.5 billion increase in earnings from the current $1.2 billion.
Uncover how Agilent Technologies’ forecasts yield a $167.57 fair value, a 9% upside to its current price.
Four fair value estimates from the Simply Wall St Community span from US$122.33 to US$167.57 per share, showing wide variation in outlooks. While community views differ, the ongoing risk around tariff-driven costs could weigh on future margins, check out other perspectives to see how investors factor this into their analyses.